Equities

ProQR Therapeutics NV

ProQR Therapeutics NV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.78
  • Today's Change-0.02 / -1.11%
  • Shares traded69.95k
  • 1 Year change+15.58%
  • Beta0.3910
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform5
Hold1
Sell0
Strong Sell0

Share price forecast in EUR

The 6 analysts offering 12 month price targets for ProQR Therapeutics NV have a median target of 5.07, with a high estimate of 6.08 and a low estimate of 2.18. The median estimate represents a 184.68% increase from the last price of 1.78.
High241.7%6.08
Med184.7%5.07
Low22.3%2.18

Earnings history & estimates in EUR

On Aug 08, 2024, ProQR Therapeutics NV reported 2nd quarter 2024 losses of -0.03 per share. This result exceeded the -0.13 consensus loss of the 5 analysts covering the company and exceeded last year's 2nd quarter results by 70.00%.
The next earnings announcement is expected on Nov 08, 2024.
Average growth rate+17.02%
ProQR Therapeutics NV reported annual 2023 losses of -0.35 per share on Mar 13, 2024.
Average growth rate+24.03%
More ▼

Revenue history & estimates in EUR

ProQR Therapeutics N.V. had 2nd quarter 2024 revenues of 6.31m. This missed the 11.46m consensus estimate of the 5 analysts following the company. This was 804.59% above the prior year's 2nd quarter results.
Average growth rate+94.31%
ProQR Therapeutics N.V. had revenues for the full year 2023 of 9.53m. This was 135.94% above the prior year's results.
Average growth rate+129.68%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.